FSY
fevipiprant
| Created: | 2018-04-16 |
| Last modified: | 2021-03-13 |
Find Related PDB Entry |
|---|
Find related ligands:Help |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 46 |
| Chiral Atom Count | 0 |
| Bond Count | 48 |
| Aromatic Bond Count | 16 |
Chemical Component Summary | |
|---|---|
| Name | fevipiprant |
| Synonyms | (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid |
| Systematic Name (OpenEye OEToolkits) | 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]ethanoic acid |
| Formula | C19 H17 F3 N2 O4 S |
| Molecular Weight | 426.409 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 12.01 | OC(Cc1c3c(n(c1C)Cc2ccc(cc2C(F)(F)F)S(=O)(=O)C)nccc3)=O |
| SMILES | CACTVS | 3.385 | Cc1n(Cc2ccc(cc2C(F)(F)F)[S](C)(=O)=O)c3ncccc3c1CC(O)=O |
| SMILES | OpenEye OEToolkits | 2.0.6 | Cc1c(c2cccnc2n1Cc3ccc(cc3C(F)(F)F)S(=O)(=O)C)CC(=O)O |
| Canonical SMILES | CACTVS | 3.385 | Cc1n(Cc2ccc(cc2C(F)(F)F)[S](C)(=O)=O)c3ncccc3c1CC(O)=O |
| Canonical SMILES | OpenEye OEToolkits | 2.0.6 | Cc1c(c2cccnc2n1Cc3ccc(cc3C(F)(F)F)S(=O)(=O)C)CC(=O)O |
| InChI | InChI | 1.03 | InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26) |
| InChIKey | InChI | 1.03 | GFPPXZDRVCSVNR-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB12011 |
|---|---|
| Name | Fevipiprant |
| Description | Fevipiprant has been used in trials studying the treatment of Asthma, Atopic Dermatitis, and Allergic Rhinitis. |
| Synonyms | Fevipiprant |
| Categories |
|
| CAS number | 872365-14-5 |
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL3137332 |
| PubChem | 23582412 |
| ChEMBL | CHEMBL3137332 |














